(January 2007)
GLP-1 agonist weight loss medications like Wegovy and Saxenda have a high probability of causing thyroid cancer based on available evidence These medications were originally designed for diabetes and then repurposed for weight loss, which means the long-term thyroid safety data is still limited The potential benefits of GLP-1 agonists for weight loss must be carefully weighed against the significant risk of developing thyroid cancer If you're considering these medications, have a detailed conversation with your doctor about your personal thyroid cancer risk versus the weight loss benefits Do the most popular weight loss medications of our time like Wegovy and Saxenda cause thyroid cancer
Zalecane poziomy dawkowania: Dawka pocztkowa: 5 jednostek (250/250 mcg)
The use of GLP-1 medications in older adults has yet to be thoroughly studied in prospective clinical trials. Likewise, anyone with baseline osteopenia or osteoporosis may be at risk of a further decrease in bone density and an increased risk of falls and fractures, he added
BPC-157 affects different systems in the body by acting on the muscular, digestive, and nervous systems through distinct but interconnected mechanisms
Research has linked prolonged PPI use to: Nutrient deficiencies (magnesium, calcium, iron, vitamin B12) (5) Increased risk of bone fractures and osteoporosis (6) Gut dysbiosis and increased risk of SIBO (7) Low stomach acid (which has been associated with leaky gut and autoimmune conditions) Higher susceptibility to infections Potential kidney and cardiovascular concerns (8, 9) Increased risk of cancer (10) Increased risk of inflammatory bowel disease (IBD) And, of course, PPIs do not address the root cause of reflux